JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Inicio・Lista de Acciones・AbCellera Biologics Inc

AbCellera Biologics Inc

Cerrado

SectorSalud

3.21 1.9

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.04

Máximo

3.21

Métricas clave
By Trading Economics
Ingresos	-22M -57M
Ventas	-8.1M 9M
Margen de beneficio	-637.845
Empleados	596
EBITDA	-1.4M -40M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+184.81% upside

Dividendos
By Dow Jones
Próximas Ganancias	24 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-557M 1B
Apertura anterior	1.31
Cierre anterior	3.21

Noticias sobre sentimiento de mercado

By Acuity

63%

37%

297 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.99 / 2.635 Soporte y Resistencia

AbCellera Biologics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 feb 2026, 17:25 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9 feb 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9 feb 2026, 23:43 UTC

Charlas de Mercado

Gold Falls on Possible Technical Correction -- Market Talk

9 feb 2026, 23:14 UTC

Charlas de Mercado

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9 feb 2026, 22:29 UTC

Charlas de Mercado

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9 feb 2026, 22:19 UTC

Charlas de Mercado

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9 feb 2026, 22:08 UTC

Charlas de Mercado

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9 feb 2026, 22:01 UTC

Ganancias

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9 feb 2026, 21:59 UTC

Ganancias

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9 feb 2026, 21:59 UTC

Ganancias

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9 feb 2026, 21:58 UTC

Ganancias

Friedman Industries 3Q Sales $168M >FRD

9 feb 2026, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

9 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 feb 2026, 21:48 UTC

Ganancias

Friedman Industries 3Q EPS 43c >FRD

9 feb 2026, 21:17 UTC

Ganancias

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9 feb 2026, 21:13 UTC

Charlas de Mercado

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9 feb 2026, 21:04 UTC

Ganancias

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9 feb 2026, 20:30 UTC

Charlas de Mercado

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9 feb 2026, 20:02 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9 feb 2026, 19:42 UTC

Charlas de Mercado

Japan's Yield Curve Expected to Flatten -- Market Talk

9 feb 2026, 19:31 UTC

Charlas de Mercado

Nike Seen Regaining Relevance With Consumers -- Market Talk

9 feb 2026, 19:27 UTC

Charlas de Mercado

Gold Climbs Back Over $5,000/oz -- Market Talk

9 feb 2026, 19:05 UTC

Charlas de Mercado

Nike Returns to List of Hottest Brands -- Market Talk

9 feb 2026, 18:19 UTC

Charlas de Mercado

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9 feb 2026, 17:41 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9 feb 2026, 17:31 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9 feb 2026, 17:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

9 feb 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 feb 2026, 17:17 UTC

Charlas de Mercado

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9 feb 2026, 17:16 UTC

Ganancias

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc Esperado

Precio Objetivo

By TipRanks

184.81% repunte

Estimación a 12 meses

Media 9 USD 184.81%

Máximo 9 USD

Mínimo 9 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para AbCellera Biologics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.99 / 2.635Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentimiento

By Acuity

297 / 352 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.